Veneno Technologies, a Novel DRP Drug Discovery Company,Raises $2Million (¥200M Yen) in Seed Funding RoundTSUKUBA CITY, Ibaraki Prefecture, Japan, Jan. 26, 2022. Veneno Technologies Co. Ltd. ispleased to announce that it has completed fundraising of 200 million yen through a third-party
allocation of new shares to SBI Investment Co., Ltd., Tsukuba Institute of Research, Ltd., and SBI
regional activation support Co., Ltd.
The funds raised will be used to strengthen the recruitment and organizational structure, tofurther develop the Company's proprietary peptide drug discovery platform technology, andinvest in the research and development of the Company's own drug discovery pipeline using
DRP functional peptides as basic molecules to further promote DRP drug discovery.
Objective of the Fund Procurement
Veneno Suite™ is the Company's proprietary integrated DRP drug discovery technology.
The Veneno Suite™ consists of a large gene library that is created by artificially accelerating theevolution of natural DRPs (Disulfide Rich Peptides) using them as templates, a screening systemthat enables the search for target DRPs from the library in a fast and efficient manner, andtechnology that enables the efficient production of various DRPs in a short period of time. With
this funding, we will further refine these technologies and accelerate DRP drug discovery(pharmaceuticals, research reagents, agrochemicals, biostimulants, and various other "drugs").

Our mission is to contribute to the advancement of medicine by providing new drugs for targets
such as membrane proteins that have been difficult to discover, and for intractable diseases
related to these targets. In order to fulfill this mission, we will strengthen the following points
through this fundraising.
•••
•
•
•

Appointment of high-level researchers and opening of new laboratories to advance DRP
drug discovery.
Expansion of the DRP focused library (DRP Space™).
Strengthen and expand the pipeline of the DRP rapid search system (PERISS™) (promotejoint research).
Development of DRP manufacturing technology (Super Secrete™) including
establishment of high-efficiency, low-volume, high-mix manufacturing technology.
This funding will enable us to further refine our proprietary large-scale library, highspeed screening technology, and high-efficiency DRP manufacturing technology toaccelerate our goal of DRP drug discovery.
We expect that we will be able to take a concrete step toward the establishment of anew paradigm using DRP as a new drug discovery platform molecule following antibodydrugs.

Investor Comments
Mr. Jun Hasegawa, Manager, Investment Division, SBI Investment Co. noted, "Veneno
Technologies has developed an innovative technology to turn functional peptides, calledDRPs, into pharmaceuticals. We have decided to invest in Veneno Technologies because
we see the potential in their technology and want to take on the challenge ofdeveloping new modalities together. We hope that our technology will lead to thedevelopment of many innovative new drugs in the future.”
Mr. Masato Suzuki, Senior Researcher, Consulting Department, Tsukuba ResearchInstitute, Inc. said, “Veneno Technologies is a drug discovery venture that uses thistechnology to develop drugs that target ion channels, which remain untapped as drugtargets.”
About Veneno Technologies, Inc.
Veneno Technologies was established to accelerate the research and development of DRP
functional peptides and to contribute to advanced and sustainable medicine and society. Thecompany was established to accelerate the research and development of DRP functional
peptides and to contribute to advanced and sustainable medicine and society.
By integrating innovative DRP discovery technologies that have been researched for many years
at the National Institute of Advanced Industrial Science and Technology (AIST) and DRP
manufacturing technologies that are currently being researched and developed, we will leadthe research and development of various DRP drug discovery technologies such as new drugs,
research reagents, agrochemicals and biostimulants.

Veneno Technologies, Inc. Veneno Technologies has entered into a patent license agreementwith AIST under AIST's technology transfer program. Veneno Technologies has been granted apatent license agreement and the title of AIST Technology Transfer Venture by AIST.
Company Profile
Company name: Veneno Technologies Corporation
Location: Tsukuba City Industrial Promotion Center, 2-5-1 Azuma, Tsukuba City, Ibaraki
Prefecture
Establishment: July 9, 2020
The company is engaged in the discovery, research and development of peptide DRPs for ion
channels, transporters, GPCRs and other membrane proteins using Veneno Suite™.
Business description: URL: https://veneno.co.jp/Notes:1) Disulfide-Rich Peptide (DRP):
Disulfide-Rich Peptide (DRP): A generic term for peptides of about 20 to 60 amino acid residues that havea characteristic structure with three or more disulfide bonds in the molecule.
DRPs are potent bioactive peptides widely found in nature, from bacteria to humans, and have beenstudied extensively in animal venoms. Since animals use DRPs as a major component of venom and have
evolved DRP peptides to be potent even in small amounts, DRPs are highly active and selective against ion
channels and receptors. In addition, DRPs have multiple disulfides in their molecules. DRPs are highly
stable against heat, pH, and degrading enzymes compared to linear peptides due to their tight molecular
structure with multiple disulfide bonds in the molecule.
In recent years, DRP has attracted attention as a new basic molecule for drug discovery.
Low-molecular-weight compounds and antibodies, which are the mainstream of existing drug molecules,
are not suitable for designing drug molecules for ion channels and GPCR due to their molecularcharacteristics.
DRPs are excellent natural agonists of ion channels and GPCRs, and have been applied to pharmaceuticals
and diagnostics. However, DRPs are difficult to synthesize chemically due to their complex molecularstructure, and effective drug screening methods (molecular discovery methods) for targeting membraneproteins are limited. Therefore, contrary to expectations for DRPs as functional components, theirpractical application has been slow to progress.
2) Veneno Suite™:
Focusing on the usefulness of DRPs as functional peptides, the Veneno Suite™ was constructed bycombining a method for searching for DRPs targeting membrane proteins developed at the National
Institute of Advanced Industrial Science and Technology (AIST) with a simple and inexpensive syntheticmethod.
The Veneno Suite™ consists of three core technologies: (1) DRP Space™: Technology for creating a large
DRP focused library, (2) PERISS™: High speed screening technology using periplasmic display method, (3)Super Secrete™: Production technology using E. coli secretion method
3) Membrane proteins such as ion channels, transporters, and GPCRs:
In order for a cell to carry out its biological activities, it is necessary to maintain a constant environment
inside and outside the cell, as well as to maintain a constant supply of inorganic ions and many watersoluble organic substances that are involved in biological metabolism.
In order for cells to carry out their biological activities, it is necessary to maintain a constant environment
inside and outside the cell, and to allow the passage of molecules that cannot penetrate the cell

membrane (lipid bilayer membrane), such as inorganic ions and many water-soluble organic substances
involved in biological metabolism.
This special "passageway" is called the lipid bilayer. These special "passageways" are ion channels
composed of membrane proteins and are called transporters.
G protein-coupled receptors (GPCRs), on the other hand, receive extracellular neurotransmitters andhormones and transmit their signals to the inside of the cell, and are involved in maintaining homeostasis
inside and outside the cell. There are various types of ion channels, transporters, and GPCRs, and they areinvolved in many diseases.
Therefore, they are important drug discovery targets.

For inquiries regarding this release, please contact:
Veneno Technologies Co.
info@veneno.co.jp